Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetu
After two recent deaths in gene therapy clinical trials, the industry needs to be more open to sharing information to protect participants.
It’s time to end the “skin in the game” experiment in health insurance and reform the broken system.
Action The U.S. Food and Drug Administration has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding
Thursday, January 23, 2025, San Francisco, California, 6:15 PM – 8:15 PM Pacific Time (9:15 PM – 11:15 PM Eastern Time) Location San Francisco Marriott…
Acute Myeloid Leukemia with NUP98-RARG Gene Fusion Similar to Acute Promyelocytic Leukemia: Case Report and Literature Review
In a cohort of 166 patients with lung adenocarcinoma, Guégan et al. show that CD8+ T cell exhaustion is associated with resistance to immune checkpoint inhibitor. They…
The tumor microenvironments (TME) of diffuse large B-cell lymphoma (DLBCL) subgroups have remained poorly characterized. Here, we dissected the composition and spatial organization of the…
Abdominal Radiology – Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) / computed tomography (CT) has become essential in managing prostate cancer, offering superior…
Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.
